Chronic Thromboembolic Pulmonary Hypertension

Symptoms

Common signs and symptoms of Chronic Thromboembolic Pulmonary Hypertension include:

Progressive shortness of breath during physical activity

Fatigue and weakness that worsens over time

Chest pain or discomfort, especially with exertion

Rapid heartbeat or heart palpitations

Dizziness or fainting spells during activity

Persistent dry cough

Swelling in legs, ankles, or abdomen

Bluish tint to lips or fingernails

Reduced exercise tolerance compared to previous abilities

Feeling breathless even during rest in advanced stages

When to see a doctor

If you experience severe or worsening symptoms, seek immediate medical attention. Always consult with a healthcare professional for proper diagnosis and treatment.

Causes & Risk Factors

Several factors can contribute to Chronic Thromboembolic Pulmonary Hypertension.

CTEPH develops when blood clots in the pulmonary arteries fail to dissolve naturally and instead become organized into permanent scar tissue.

CTEPH develops when blood clots in the pulmonary arteries fail to dissolve naturally and instead become organized into permanent scar tissue. Normally, the body's clot-dissolving system breaks down blood clots within weeks to months. In CTEPH, this process fails, and the clots transform into fibrous material that permanently narrows or blocks the lung's blood vessels. Think of it like a river where fallen trees don't wash away during spring floods but instead collect debris and create permanent dams.

The initial trigger is usually a pulmonary embolism, where blood clots travel from deep veins in the legs or pelvis to the lungs.

The initial trigger is usually a pulmonary embolism, where blood clots travel from deep veins in the legs or pelvis to the lungs. However, only about 1-4% of people who survive a pulmonary embolism go on to develop CTEPH. This suggests that certain individuals have underlying problems with their clot-dissolving mechanisms or blood vessel healing processes. Some people develop CTEPH without any clear history of blood clots, indicating that small, unnoticed clots may have occurred over time.

Researchers believe that chronic inflammation, genetic factors affecting blood clotting, and problems with the body's fibrinolytic system all contribute to CTEPH development.

Researchers believe that chronic inflammation, genetic factors affecting blood clotting, and problems with the body's fibrinolytic system all contribute to CTEPH development. Certain blood disorders, autoimmune conditions, and infections may also increase the likelihood that clots will organize into permanent scar tissue rather than dissolving naturally. The exact mechanisms are still being studied, but the common thread involves the body's inability to properly clear clotted material from the pulmonary circulation.

Risk Factors

Previous history of pulmonary embolism or deep vein thrombosis
Recurrent blood clots or clotting disorders
Spleen removal (splenectomy)
Chronic inflammatory conditions like inflammatory bowel disease
Blood disorders such as antiphospholipid syndrome
History of infected pacemaker leads or IV catheters
Thyroid hormone replacement therapy
History of cancer, especially blood cancers

Diagnosis

How healthcare professionals diagnose Chronic Thromboembolic Pulmonary Hypertension:

1
Diagnosing CTEPH requires a high index of suspicion because early symptoms closely resemble other forms of pulmonary hypertension and heart disease.
Diagnosing CTEPH requires a high index of suspicion because early symptoms closely resemble other forms of pulmonary hypertension and heart disease. The diagnostic journey typically begins when someone reports progressive shortness of breath and reduced exercise tolerance, especially if they have a history of blood clots. The initial evaluation includes a thorough physical exam, where doctors listen for specific heart sounds and check for signs of right heart strain, along with basic blood tests and an electrocardiogram.
2
The key diagnostic test is a ventilation-perfusion (V/Q) scan, which shows characteristic patterns of blood flow obstruction in CTEPH that appear as wedge-shaped areas where no blood flows despite normal air ventilation.
The key diagnostic test is a ventilation-perfusion (V/Q) scan, which shows characteristic patterns of blood flow obstruction in CTEPH that appear as wedge-shaped areas where no blood flows despite normal air ventilation. This test can distinguish CTEPH from other forms of pulmonary hypertension with high accuracy. CT pulmonary angiography provides detailed images of the pulmonary arteries, revealing chronic clots, scar tissue, and the typical mosaic pattern of blood flow that characterizes CTEPH. Right heart catheterization measures the exact pressures in the pulmonary arteries and confirms the diagnosis while assessing how severe the condition has become.
3
Pulmonary angiography, considered the gold standard, involves injecting contrast dye directly into the pulmonary arteries to create detailed images of the blockages.
Pulmonary angiography, considered the gold standard, involves injecting contrast dye directly into the pulmonary arteries to create detailed images of the blockages. This test not only confirms the diagnosis but also maps out exactly where the obstructions are located, which is essential for planning surgical treatment. Additional tests may include echocardiography to assess right heart function, pulmonary function tests, and blood work to rule out other conditions that can mimic CTEPH symptoms.

Complications

The most serious complication of untreated CTEPH is progressive right heart failure, which develops as the heart muscle weakens from the constant strain of pumping blood through blocked pulmonary arteries.
Over time, the right ventricle enlarges and loses its ability to pump effectively, leading to fluid retention, severe fatigue, and eventually death if left untreated.
This progression can take years, but once right heart failure becomes advanced, treatment options become more limited and outcomes less favorable.
Other complications can include recurrent blood clots, since the underlying tendency toward clot formation often persists.
Severe shortness of breath can progress to the point where people become unable to perform basic daily activities or may require supplemental oxygen.
Some patients develop secondary complications from reduced activity levels, including muscle weakness, bone loss, and depression.
In rare cases, severely elevated pulmonary pressures can cause life-threatening arrhythmias or sudden death.
However, with early diagnosis and appropriate treatment, most of these complications can be prevented or significantly improved, highlighting the importance of recognizing CTEPH symptoms and seeking specialized care promptly.

Prevention

Because CTEPH typically develops after pulmonary embolism, the most effective prevention strategy focuses on proper treatment and follow-up care for people who have had blood clots in their lungs.
Anyone who has experienced a pulmonary embolism should receive appropriate anticoagulation therapy for the recommended duration and maintain regular follow-up with their healthcare provider.
If symptoms like shortness of breath, fatigue, or reduced exercise tolerance persist or worsen after completing treatment for a pulmonary embolism, patients should seek prompt medical evaluation rather than assuming these symptoms are normal.
Preventing the initial blood clots that can lead to CTEPH involves standard clot prevention measures: staying active and mobile during long periods of sitting, maintaining a healthy weight, managing underlying conditions that increase clotting risk, and following medical advice about anticoagulation if you have known clotting disorders.
People with risk factors for blood clots should discuss prevention strategies with their doctors, especially before surgery, long flights, or periods of immobility.
Unfortunately, there's no guaranteed way to prevent CTEPH from developing after a pulmonary embolism, since we don't fully understand why some people's clots fail to dissolve properly while others heal normally.
Early recognition and treatment remain the best approaches to preventing the progression from acute blood clots to chronic, life-threatening pulmonary hypertension.
Research is ongoing to identify biomarkers that might predict who is at highest risk for developing CTEPH after a pulmonary embolism.

Treatment Approaches

The primary treatment for CTEPH is pulmonary endarterectomy (PEA), a specialized surgical procedure that can potentially cure the condition by physically removing the organized clots and scar tissue from the pulmonary arteries.

The primary treatment for CTEPH is pulmonary endarterectomy (PEA), a specialized surgical procedure that can potentially cure the condition by physically removing the organized clots and scar tissue from the pulmonary arteries. This complex surgery requires tremendous expertise and is performed at only a few specialized centers worldwide. During the procedure, surgeons work under hypothermia and temporary circulatory arrest to carefully peel away the chronic clot material from the arterial walls. Success rates are high when patients are good surgical candidates, with most people experiencing dramatic improvement in symptoms and lung pressures.

Surgical

For patients who aren't candidates for surgery due to the location of their clots or other medical factors, balloon pulmonary angioplasty (BPA) offers an alternative approach.

For patients who aren't candidates for surgery due to the location of their clots or other medical factors, balloon pulmonary angioplasty (BPA) offers an alternative approach. This minimally invasive procedure uses tiny balloons to open up blocked vessels, similar to angioplasty used for heart arteries. BPA is typically performed in multiple sessions over several months, gradually opening more vessels each time. While not as dramatically effective as surgery, BPA can significantly improve symptoms and quality of life for many patients.

Surgical

Medical therapy plays an important supporting role, particularly for patients waiting for surgery or those not eligible for procedures.

Medical therapy plays an important supporting role, particularly for patients waiting for surgery or those not eligible for procedures. Medications used include riociguat, specifically approved for CTEPH, which helps relax pulmonary blood vessels and improve blood flow. Other pulmonary vasodilators like epoprostenol, treprostinil, and sildenafil may also be prescribed. Lifelong anticoagulation with warfarin or newer oral anticoagulants is essential to prevent new clot formation. Some patients may also need diuretics to manage fluid retention and oxygen therapy for severe cases.

SurgicalMedicationTherapy

Rehabilitation and supportive care are equally important components of treatment.

Rehabilitation and supportive care are equally important components of treatment. Pulmonary rehabilitation programs help patients regain strength and endurance while learning breathing techniques and energy conservation strategies. Regular monitoring includes periodic imaging studies, heart catheterizations, and functional assessments to track progress and adjust treatment as needed. For the small percentage of patients with severe disease who don't respond to other treatments, lung transplantation may be considered as a final option.

Living With Chronic Thromboembolic Pulmonary Hypertension

Living with CTEPH requires adapting to physical limitations while maintaining hope for significant improvement with proper treatment. Many people find that pacing activities and avoiding overexertion helps manage symptoms while they await or recover from treatment. Breaking larger tasks into smaller steps, using assistive devices when needed, and planning rest periods throughout the day can help conserve energy. Staying as physically active as possible within your limitations helps maintain muscle strength and cardiovascular fitness, though any exercise program should be developed with your medical team's guidance.

Emotional support plays a crucial role in managing CTEPH, particularly given the often lengthy journey to diagnosis and the complexity of treatment decisions.Emotional support plays a crucial role in managing CTEPH, particularly given the often lengthy journey to diagnosis and the complexity of treatment decisions. Connecting with other patients through support groups, either in person or online, can provide valuable practical advice and emotional understanding. Many people find it helpful to learn as much as possible about their condition and treatment options, as this knowledge can reduce anxiety and help them advocate effectively for their care. Working with a medical team experienced in CTEPH is essential, even if it requires traveling to a specialized center.

Practical daily management strategies include: monitoring symptoms and reporting any changes promptly to your healthcare team, taking medications exactly as prescribed, maintaining a healthy diet low in sodium to reduce fluid retention, getting recommended vaccinations to prevent respiratory infections, and planning ahead for activities that might be physically demanding.Practical daily management strategies include: monitoring symptoms and reporting any changes promptly to your healthcare team, taking medications exactly as prescribed, maintaining a healthy diet low in sodium to reduce fluid retention, getting recommended vaccinations to prevent respiratory infections, and planning ahead for activities that might be physically demanding. Many patients benefit from pulmonary rehabilitation programs that teach breathing techniques, energy conservation, and safe exercise methods. With proper treatment, many people with CTEPH can return to work, travel, and enjoy most normal activities, though some may need to make permanent lifestyle adjustments based on their individual response to treatment.

Latest Medical Developments

Latest medical developments are being researched.

Frequently Asked Questions

How is CTEPH different from other types of pulmonary hypertension?

CTEPH is the only form of pulmonary hypertension that's potentially curable with surgery. Unlike other types that result from problems with the small blood vessels or heart, CTEPH is caused by organized blood clots blocking larger pulmonary arteries. This makes it treatable with procedures that physically remove the blockages.

Can I exercise safely with CTEPH?

Exercise is generally beneficial but should be carefully planned with your medical team. Most patients can engage in light to moderate activities like walking, swimming, or stationary cycling. Avoid activities that cause severe shortness of breath, chest pain, or dizziness. Pulmonary rehabilitation programs can help you exercise safely.

Will I need to take blood thinners for life?

Yes, most people with CTEPH require lifelong anticoagulation to prevent new blood clots from forming. Even after successful surgery, the underlying tendency toward clot formation usually persists. Your doctor will monitor your blood levels regularly and adjust medications as needed.

How successful is pulmonary endarterectomy surgery?

When performed at experienced centers on appropriate candidates, PEA surgery has excellent success rates with significant symptom improvement in 85-90% of patients. However, not all patients are surgical candidates, and the procedure requires specialized expertise available at only a few medical centers worldwide.

Can CTEPH come back after successful treatment?

True recurrence of CTEPH after successful pulmonary endarterectomy is rare, occurring in less than 5% of patients. However, new blood clots can form if anticoagulation is inadequate. Some patients may have persistent elevated pressures due to small vessel disease that wasn't correctable with surgery.

How long does it typically take to diagnose CTEPH?

Unfortunately, diagnosis is often delayed by 1-2 years or more because symptoms develop gradually and mimic other conditions. Many patients see multiple doctors before getting the correct diagnosis. Having a history of blood clots and knowing the symptoms can help speed up the diagnostic process.

What should I do if I had a pulmonary embolism and still feel short of breath?

Don't assume ongoing symptoms are normal after a pulmonary embolism. If you continue to experience shortness of breath, fatigue, or reduced exercise tolerance months after your initial treatment, discuss this with your doctor and ask about CTEPH evaluation. Early detection makes a significant difference in outcomes.

Is balloon pulmonary angioplasty as effective as surgery?

BPA is less dramatically effective than surgery but offers significant benefits for patients who aren't surgical candidates. Most people experience meaningful symptom improvement and better quality of life. The procedure can be repeated if needed and has lower risks than major surgery.

Can pregnancy be safe with CTEPH?

Pregnancy with CTEPH carries significant risks and requires specialized care from a high-risk maternal-fetal medicine team. The cardiovascular stress of pregnancy can worsen pulmonary hypertension. If you're considering pregnancy, discuss this thoroughly with your pulmonary hypertension specialist first.

Are there any new treatments being developed for CTEPH?

Research continues into improved surgical techniques, better balloon angioplasty methods, and new medications. Scientists are also studying ways to predict who might develop CTEPH after a pulmonary embolism and investigating combination therapies that might improve outcomes for patients who aren't surgical candidates.

Update History

Apr 4, 2026v1.0.0

Published by DiseaseDirectory